Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMRNNASDAQ:IMRXNASDAQ:NVCTNASDAQ:OCGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMRNAmarin$10.43-6.7%$9.62$7.08▼$20.60$214.17M1.3873,953 shs55,645 shsIMRXImmuneering$1.45-0.7%$1.51$1.00▼$3.83$52.54M-0.252.35 million shs47,041 shsNVCTNuvectis Pharma$10.49-4.3%$8.48$4.44▼$11.80$256.38M-0.11124,729 shs233,977 shsOCGNOcugen$0.72-2.4%$0.64$0.52▼$2.06$210.02M3.784.70 million shs2.84 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMRNAmarin0.00%+14.49%+11.60%-16.81%-40.64%IMRXImmuneering0.00%+14.17%-12.65%-29.61%-3.33%NVCTNuvectis Pharma0.00%+18.40%+8.70%+60.15%+56.33%OCGNOcugen0.00%+5.86%-0.65%-7.79%-39.05%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMRNAmarin0.566 of 5 stars1.04.00.00.02.70.00.0IMRXImmuneering3.7837 of 5 stars3.25.00.00.03.63.31.3NVCTNuvectis Pharma2.6453 of 5 stars3.50.00.00.02.65.00.6OCGNOcugen0.9515 of 5 stars3.50.00.00.01.60.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMRNAmarin 2.00Hold$7.00-32.89% DownsideIMRXImmuneering 2.33Hold$12.50762.07% UpsideNVCTNuvectis Pharma 3.00Buy$15.6749.35% UpsideOCGNOcugen 3.00Buy$6.33780.61% UpsideCurrent Analyst Ratings BreakdownLatest IMRX, OCGN, AMRN, and NVCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/17/2025AMRNAmarinThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSell ➝ Sell$20.00 ➝ $7.004/10/2025IMRXImmuneeringNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.004/2/2025NVCTNuvectis PharmaMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$17.003/24/2025IMRXImmuneeringChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.003/21/2025IMRXImmuneeringNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.003/17/2025NVCTNuvectis PharmaLaidlawSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$19.003/6/2025OCGNOcugenChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$6.00 ➝ $7.003/6/2025OCGNOcugenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.002/25/2025NVCTNuvectis PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$21.00 ➝ $11.002/13/2025OCGNOcugenChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.002/13/2025OCGNOcugenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $8.00(Data available from 4/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMRNAmarin$228.61M0.94N/AN/A$1.35 per share7.73IMRXImmuneering$320K163.06N/AN/A$3.09 per share0.47NVCTNuvectis PharmaN/AN/AN/AN/A$0.70 per shareN/AOCGNOcugen$4.06M51.79N/AN/A$0.16 per share4.50Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMRNAmarin-$59.11M-$4.00N/AN/AN/A-16.33%-7.22%-4.96%5/7/2025 (Estimated)IMRXImmuneering-$53.47M-$2.03N/AN/AN/AN/A-79.19%-69.08%5/6/2025 (Estimated)NVCTNuvectis Pharma-$22.26M-$1.11N/AN/AN/AN/A-155.80%-104.02%5/6/2025 (Estimated)OCGNOcugen-$63.08M-$0.19N/AN/AN/A-532.51%-154.75%-90.79%5/13/2025 (Estimated)Latest IMRX, OCGN, AMRN, and NVCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025OCGNOcugen-$0.06N/AN/AN/AN/AN/A5/7/2025Q1 2025AMRNAmarin-$0.06N/AN/AN/A$50.75 millionN/A5/6/2025Q1 2025IMRXImmuneering-$0.41N/AN/AN/AN/AN/A5/6/2025Q1 2025NVCTNuvectis Pharma-$0.30N/AN/AN/AN/AN/A3/20/2025Q4 2024IMRXImmuneering-$0.42-$0.58-$0.16-$0.58N/AN/A3/12/2025Q4 2024AMRNAmarin-$1.20-$2.40-$1.20-$0.12$32.37 million$62.31 million3/5/2025Q4 2024OCGNOcugen-$0.05-$0.05N/A-$0.05$0.30 million$0.76 million3/4/2025Q4 2024NVCTNuvectis Pharma-$0.28-$0.36-$0.08-$0.36N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMRNAmarinN/AN/AN/AN/AN/AIMRXImmuneeringN/AN/AN/AN/AN/ANVCTNuvectis PharmaN/AN/AN/AN/AN/AOCGNOcugenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMRNAmarinN/A3.232.11IMRXImmuneeringN/A7.997.99NVCTNuvectis PharmaN/A2.742.74OCGNOcugen0.042.582.58Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMRNAmarin22.25%IMRXImmuneering67.65%NVCTNuvectis Pharma96.77%OCGNOcugen10.27%Insider OwnershipCompanyInsider OwnershipAMRNAmarin1.96%IMRXImmuneering25.00%NVCTNuvectis Pharma35.78%OCGNOcugen4.29%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMRNAmarin36020.53 million402.62 millionOptionableIMRXImmuneering6035.99 million23.29 millionNot OptionableNVCTNuvectis Pharma823.39 million12.41 millionNot OptionableOCGNOcugen80292.01 million278.82 millionOptionableIMRX, OCGN, AMRN, and NVCT HeadlinesRecent News About These CompaniesOcugen Inc. stock rises Tuesday, still underperforms marketApril 23, 2025 | marketwatch.comIs Ocugen Inc. (NASDAQ:OCGN) the Best Penny Stock to Invest in Under $1?April 17, 2025 | msn.comOcugen CEO to Present at Prestigious Cell & Gene Meeting on the MediterraneanApril 10, 2025 | msn.comOcugen management to meet with MaximApril 9, 2025 | markets.businessinsider.comOcugen to Present at the 2025 Cell & Gene Meeting on the MedApril 8, 2025 | globenewswire.comStargardt Disease Market Predicted to See Upsurge Through 2034, Highlights DelveInsight | Acucela, Astellas Pharma, Alkeus PharmaApril 7, 2025 | theglobeandmail.comChardan Capital Forecasts Ocugen FY2025 EarningsMarch 28, 2025 | marketbeat.comOcugen to move forward with dosing of second cohort of phase 1 clinical trial of OCU200March 21, 2025 | ophthalmologytimes.comOcugen receives DSMB approval to continue dosing in Phase I trial of OCU200March 19, 2025 | clinicaltrialsarena.comOcugen Advances OCU200 Clinical Trial Amid Promising Safety ResultsMarch 19, 2025 | msn.comOcugen says DSMB approves dosing Cohort 2 in OCU200 clinical trialMarch 18, 2025 | markets.businessinsider.comData and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular EdemaMarch 18, 2025 | globenewswire.comOcugen, Inc. (NASDAQ:OCGN) Q4 2024 Earnings Call TranscriptMarch 6, 2025 | msn.comAttention Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Mercury Systems, Inc. (NASDAQ: MRCY); MGP Ingredients, Inc. (NASDAQ: MGPI); and Ocugen, Inc. (NASDAQ: OCGN): Grabar Law Office Investigates Claims on Your BehalfMarch 6, 2025 | financialpost.comOcugen, Inc. (OCGN) Q4 2024 Earnings Call TranscriptMarch 6, 2025 | seekingalpha.comOcugen reports Q4 EPS (5c), consensus (5c)March 6, 2025 | markets.businessinsider.comOcugen (OCGN) Q4 2024 Earnings Call TranscriptMarch 6, 2025 | msn.comOcugen Reports Progress in Gene Therapy TrialsMarch 5, 2025 | tipranks.comOcugen, Inc. Reports Progress on Clinical Trials and FDA Alignment for OCU410ST in Stargardt Disease, Highlights Positive Long-Term Data for OCU400March 5, 2025 | quiverquant.comOcugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial ResultsMarch 5, 2025 | globenewswire.comNoble Financial Sticks to Its Buy Rating for Ocugen (OCGN)March 4, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMRX, OCGN, AMRN, and NVCT Company DescriptionsAmarin NASDAQ:AMRN$10.43 -0.75 (-6.71%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$10.44 +0.01 (+0.13%) As of 04/25/2025 07:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.Immuneering NASDAQ:IMRX$1.45 -0.01 (-0.68%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$1.45 0.00 (-0.07%) As of 04/25/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.Nuvectis Pharma NASDAQ:NVCT$10.49 -0.47 (-4.29%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$10.31 -0.18 (-1.72%) As of 04/25/2025 05:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.Ocugen NASDAQ:OCGN$0.72 -0.02 (-2.40%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$0.72 0.00 (-0.58%) As of 04/25/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 04/21 - 04/25 Bears Can Reap Big Benefits With These 3 Short ETF Bets If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains? Markets Think Robinhood Earnings Could Send the Stock Up Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
